BIOMAT Database Logo BIOMAT Database Logo

Follow up of soluble IL-2 receptor level in metastatic malignant melanoma patients treated by chemoimmunotherapy. 1994

C Soubrane, and R Mouawad, and M Ichen, and J Suissa, and C Borel, and E Vuillemin, and A Benhammouda, and J P Bizzari, and M Weil, and D Khayat
Department of Medical Oncology, Salpétrière Hospital, Paris, France.

Immunological parameters following chemoimmunotherapy combination were studied in 31 patients with metastatic malignant melanoma. They received Cisplatin (100 mg/m2) on day 1 and 28, recombinant IL-2 (rIL-2; Eurocetus) in continuous infusion from day 3 to 6, 17 to 21, 31 to 34 and 45 to 49. Interferon-alpha (IFN-alpha; Roche) was given subcutaneously three times weekly. No significant change in CD4/CD8 ratio at onset or during treatment was observed between responder (n = 19) and non-responder (n = 12) patients. Regarding the IL-2 receptor (IL-2R) study, the percentage of cells expressing Tac (p55) receptor did not change either for healthy volunteers (n = 20) and patients before any therapy, or between responder and non-responder patients. Concerning serum soluble IL-2R shedding before therapy, we observed a significant increase (P = 0.001) in patients (79 +/- 40 pM) compared with healthy donors (30 +/- 15 pM), but no significant variation was seen between responder and non-responder patients. In contrast, during the treatment, the soluble IL-2R level increased in both groups but, interestingly, a significant difference was found between responder and non-responder patients from day 7 (P < 0.05) to day 21 (P < or = 0.01), suggesting that the cells from non-responder may be slower in becoming stimulated. This finding is the most striking point of our study and suggests that sIL-2R might be an early predictive factor of the clinical response as obtained by logistic regression (P = 0.0063). Therefore patients with a serum soluble IL-2R level greater than 250 pM at day 21 have a 12-fold more chance of undergoing a clinical response.

UI MeSH Term Description Entries
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D008297 Male Males
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

C Soubrane, and R Mouawad, and M Ichen, and J Suissa, and C Borel, and E Vuillemin, and A Benhammouda, and J P Bizzari, and M Weil, and D Khayat
Differential responses to chemoimmunotherapy in patients with metastatic malignant melanoma.
August 1997, European journal of cancer (Oxford, England : 1990),
C Soubrane, and R Mouawad, and M Ichen, and J Suissa, and C Borel, and E Vuillemin, and A Benhammouda, and J P Bizzari, and M Weil, and D Khayat
Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma.
January 2007, The Cochrane database of systematic reviews,
C Soubrane, and R Mouawad, and M Ichen, and J Suissa, and C Borel, and E Vuillemin, and A Benhammouda, and J P Bizzari, and M Weil, and D Khayat
Plasma soluble interleukin-2 receptor (IL-2RS) level and activation markers in blood in the follow-up of renal allograft patients.
August 1990, Transplantation proceedings,
C Soubrane, and R Mouawad, and M Ichen, and J Suissa, and C Borel, and E Vuillemin, and A Benhammouda, and J P Bizzari, and M Weil, and D Khayat
[Serum soluble IL-2 receptor level in patients with sarcoidosis].
March 1991, Nihon Kyobu Shikkan Gakkai zasshi,
C Soubrane, and R Mouawad, and M Ichen, and J Suissa, and C Borel, and E Vuillemin, and A Benhammouda, and J P Bizzari, and M Weil, and D Khayat
Serum-soluble IL-2 receptor and IL-6 levels in patients with melanoma.
January 1997, Oncology,
C Soubrane, and R Mouawad, and M Ichen, and J Suissa, and C Borel, and E Vuillemin, and A Benhammouda, and J P Bizzari, and M Weil, and D Khayat
Follow-up of malignant melanoma patients.
June 1978, The Journal of dermatologic surgery and oncology,
C Soubrane, and R Mouawad, and M Ichen, and J Suissa, and C Borel, and E Vuillemin, and A Benhammouda, and J P Bizzari, and M Weil, and D Khayat
WITHDRAWN: Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma.
February 2018, The Cochrane database of systematic reviews,
C Soubrane, and R Mouawad, and M Ichen, and J Suissa, and C Borel, and E Vuillemin, and A Benhammouda, and J P Bizzari, and M Weil, and D Khayat
Lymphocyte function related to survival curves in patients with metastatic melanoma treated by chemoimmunotherapy.
January 1978, Medical and pediatric oncology,
C Soubrane, and R Mouawad, and M Ichen, and J Suissa, and C Borel, and E Vuillemin, and A Benhammouda, and J P Bizzari, and M Weil, and D Khayat
[The soluble IL-2 receptor in malignant hemopathies].
October 1992, Recenti progressi in medicina,
C Soubrane, and R Mouawad, and M Ichen, and J Suissa, and C Borel, and E Vuillemin, and A Benhammouda, and J P Bizzari, and M Weil, and D Khayat
Novel management of pruritus in patients treated with IL-2 for metastatic renal cell carcinoma and malignant melanoma.
January 2010, Journal of immunotherapy (Hagerstown, Md. : 1997),
Copied contents to your clipboard!